Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
Baxfendy works in a fundamentally different way from current therapies
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
Highlighting KEYTRUDA & expanding cancer pipeline
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Academia-industry partnership to promote indigenous technology commercialization in biotech sector
Subscribe To Our Newsletter & Stay Updated
